Peptide Degrader‐Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma
- 29 October 2024
- journal article
- Published by Wiley in Angewandte Chemie
- Vol. 136 (48)
Abstract
METTL3 has emerged as a promising therapeutic target in cancer treatment, although its oncogenic functions in melanoma development and potential for therapeutic targeting drug have not been fully explored. In this study, we define the oncogenic role of METTL3 in melanoma development and progression. Building on this insight, we examine our recently designed peptide inhibitor RM3 , which targets the binding interface of METTL3/14 complex for disruption and subsequent ubiquitin‐mediated proteasomal degradation via the E3 ligase STUB1. RM3 treatment reduces proliferation, migration, and invasion, and induces apoptosis in melanoma cells in vitro and in vivo. Subsequent transcriptomic analysis identified changes in immuno‐related genes following RM3 ‐mediated suppression of METTL3/14 N 6 ‐methyladenosine (m 6 A) methyltransferase activity, suggesting a potential for interaction with immunotherapy. A combination treatment of RM3 with anti‐PD‐1 antibody results in significantly higher beneficial tumor response in vivo, with a good safety profile. Collectively, these findings not only delineate the oncogenic role of METTL3 in melanoma but also showcase RM3 , acting as a peptide degrader, as a novel and promising strategy for melanoma treatment.Keywords
Funding Information
- National Natural Science Foundation of China (21975068)
- Science Fund for Distinguished Young Scholars of Hunan Province (2022JJ10008)
This publication has 62 references indexed in Scilit:
- Discovery of a PROTAC degrader for METTL3-METTL14 complexCell Chemical Biology, 2024
- Glutathione Depletion‐Induced Activation of Dimersomes for Potentiating the Ferroptosis and Immunotherapy of “Cold” TumorAngewandte Chemie International Edition, 2022
- METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translationCancer Letters, 2021
- m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesityCell Reports, 2021
- Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid TumorsAngewandte Chemie International Edition, 2020
- RNA m6A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c‐MetJournal of Cellular Physiology, 2020
- De novo Design of Selective Membrane‐Active Peptides by Enzymatic Control of Their Conformational Bias on the Cell SurfaceAngewandte Chemie International Edition, 2019
- RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2Hepatology, 2017
- A Synthetic Loop Replacement Peptide That Blocks Canonical NF‐κB SignalingAngewandte Chemie International Edition, 2016
- Therapeutic Advances and Treatment Options in Metastatic MelanomaJAMA Oncology, 2015